scholarly journals Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice

2015 ◽  
Vol 35 (7) ◽  
pp. 1801-1808 ◽  
Author(s):  
Guruprasad P. Aithal
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Drug Induced ◽  
Pharmacogenetic Testing ◽  
Current Role ◽  
Drug Induced Liver Injury

scholarly journals EASL Clinical Practice Guidelines: Drug-induced liver injury

2019 ◽  
Vol 70 (6) ◽  
pp. 1222-1261 ◽  
Author(s):  
Raúl J. Andrade ◽  
Guruprasad P. Aithal ◽  
Einar S. Björnsson ◽  
Neil Kaplowitz ◽  
Gerd A. Kullak-Ublick ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Drug Induced ◽  
Drug Induced Liver Injury

Assessment of drug-induced liver injury in clinical practice

2008 ◽  
Vol 22 (2) ◽  
pp. 141-158 ◽  
Author(s):  
Ma Isabel Lucena ◽  
Miren García-Cortés ◽  
Raquel Cueto ◽  
JL Lopez-Duran ◽  
Raúl J Andrade
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Drug-induced liver injury and COVID-19: A review for clinical practice

2021 ◽  
Vol 13 (9) ◽  
pp. 1143-1153
Author(s):  
Gabriela Xavier Ortiz ◽  
Gabriele Lenhart ◽  
Matheus William Becker ◽  
Karin Hepp Schwambach ◽  
Cristiane Valle Tovo ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Drug Induced ◽  
Drug Induced Liver Injury

The Role of Pharmacogenetic Testing in the Evaluation of Drug-Induced Liver Injury

2016 ◽  
Vol 38 (10) ◽  
pp. e24-e25
Author(s):  
M. Stanić Benić ◽  
N. Mirošević Skvrce ◽  
N. Božina
Keyword(s):  
Liver Injury ◽  
Drug Induced ◽  
Pharmacogenetic Testing ◽  
Drug Induced Liver Injury

scholarly journals Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)

2021 ◽  
pp. flgastro-2021-101886
Author(s):  
Paul N Brennan ◽  
Peter Cartlidge ◽  
Thomas Manship ◽  
John F Dillon
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
European Association ◽  
Drug Induced ◽  
Drug Induced Liver Injury

The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

scholarly journals Translating new knowledge on drug-induced liver injury into clinical practice

2019 ◽  
Vol 11 (4) ◽  
pp. 303-310 ◽  
Author(s):  
Nelia Hernandez ◽  
Yessica Pontet ◽  
Fernando Bessone
Keyword(s):  
Clinical Practice ◽  
Liver Injury ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Diagnostic Tools ◽  
Published Data ◽  
Drug Induced ◽  
Liver Tumours ◽  
Drug Induced Liver Injury ◽  
Genetic And Environmental Factors

Drug-induced liver injury (DILI) is one of the main reasons for drug withdrawal from the market, and a cause of worldwide morbidity. Although several issues on DILI are still unsolved, there have been significant advances in new definitions and diagnosis tools. DILI is the result of a complex interaction between genetic and environmental factors, and constitutes an expanding area of investigation. DILI can mimic virtually all known hepatopathies, including vascular disorders and liver tumours. As part of this broad spectrum of clinical presentations, DILI severity ranges from asymptomatic elevations of aminotransferases to acute liver failure. Although biomarkers are emerging as valuable diagnostic tools, they are not available in clinical practice. Accurate DILI diagnosis is a challenging issue, particularly the establishing of causal relationships with the culprit agent and the exclusion of competing causes of liver injury. Given that the understanding of the mechanisms inducing DILI is growing, and both DILI causality assessment scales and the performance of international DILI networks have been improved, hepatotoxicity may be recognised earlier in clinical practice. In this review, advances and results obtained by DILI registries around the world, case characterisations, particularly those relevant to newer definitions in DILI, and the behaviour of chronic liver disease induced by drugs will be updated. In addition, recently published data on herbal and dietary supplements and new predictive scores for acute liver failure assessment will also be discussed.

Sign in / Sign up

Export Citation Format

Share Document